Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche (UMR)_S 1176, University Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
Inovarion SAS, Paris, France.
Blood. 2017 Apr 27;129(17):2443-2454. doi: 10.1182/blood-2016-06-724351. Epub 2017 Feb 17.
Recently, we have identified scavenger receptor class A member I (SR-AI) as a receptor for coagulation factor X (FX), mediating the formation of an FX reservoir at the macrophage surface. Here, we demonstrate that the FX/SR-AI-complex comprises a third protein, pentraxin-2 (PTX2). The presence of PTX2 is essential to prevent internalization of FX by SR-AI, and the presence of FX is needed to interfere with internalization of PTX2. Binding studies showed that FX, SR-AI, and PTX2 independently bind to each other (: 0.2-0.7 μM). Surprisingly, immunoprecipitation experiments revealed that FX and PTX2 circulate as a complex in plasma, and complex formation involves the FX activation peptide. No binding of PTX2 to other vitamin K-dependent proteins was observed. Short hairpin RNA-mediated inhibition of PTX2 levels in mice resulted not only in reduced levels of PTX2, but also in similarly reduced FX levels. Moreover, PTX2 and FX levels were correspondingly reduced in SR-AI-deficient mice. Analysis of 71 human plasma samples uncovered a strong correlation between FX and PTX2 plasma levels. Furthermore, plasma samples of patients with reduced FX levels (congenital/acquired FX deficiency or after anti-vitamin K treatment) were characterized by concomitantly decreased PTX2 levels. In conclusion, we identified PTX2 as a novel partner for FX, and both proteins cooperate to prevent their SR-AI-mediated uptake by macrophages. Interestingly, their respective plasma levels are interdependent. These findings seem of relevance in perspective of ongoing clinical trials, in which plasma depletion of PTX2 is used as a therapeutical approach in the management of systemic amyloidosis.
最近,我们发现清道夫受体家族 A 成员 I(SR-AI)是凝血因子 X(FX)的受体,介导 FX 在巨噬细胞表面形成储备库。在这里,我们证明 FX/SR-AI 复合物包含第三种蛋白质,即五聚素 2(PTX2)。PTX2 的存在对于防止 FX 被 SR-AI 内化是必不可少的,而 FX 的存在则需要干扰 PTX2 的内化。结合研究表明,FX、SR-AI 和 PTX2 彼此独立结合(: 0.2-0.7 μM)。令人惊讶的是,免疫沉淀实验表明 FX 和 PTX2 在血浆中作为复合物循环,并且复合物形成涉及 FX 激活肽。未观察到 PTX2 与其他维生素 K 依赖性蛋白质结合。在小鼠中用短发夹 RNA 抑制 PTX2 水平不仅导致 PTX2 水平降低,而且 FX 水平也类似降低。此外,PTX2 和 FX 水平在 SR-AI 缺陷小鼠中也相应降低。对 71 个人血浆样本的分析揭示了 FX 和 PTX2 血浆水平之间存在很强的相关性。此外,FX 水平降低(先天性/获得性 FX 缺乏或抗维生素 K 治疗后)的患者的血浆样本特征是 PTX2 水平同时降低。总之,我们确定了 PTX2 是 FX 的一种新伴侣,这两种蛋白质合作以防止它们被巨噬细胞通过 SR-AI 摄取。有趣的是,它们各自的血浆水平是相互依赖的。这些发现似乎与正在进行的临床试验有关,其中使用血浆耗尽 PTX2 作为系统性淀粉样变性管理中的治疗方法。